India’s drug regulator has mandated pharmaceutical companies to establish robust systems for tracking and reporting adverse drug reactions. This directive, stemming from Schedule M of the Drugs and Cosmetics Rules, reinforces the critical need for post-marketing surveillance to ensure patient safety. The move aligns with a global push for real-world safety data to identify rare or delayed side effects.
Blog
Drug firms told to strengthen monitoring of medicine side effects
- by The News Vista
- June 5, 2026
- 0 Comments
- Less than a minute
- 1 View
- 5 hours ago

